Taysha Gene Therapies (TSHA) Non Operating Income (2020 - 2026)

Taysha Gene Therapies has disclosed Non Operating Income across 7 years of filings, most recently posting $1.1 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $1.1 million, up 1096.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$543000.0 (down 119.11% YoY), and the FY2025 annual result was -$291000.0, down 113.47% from the prior year.
• Non Operating Income came in at $1.1 million for Q1 2026 at Taysha Gene Therapies, up from -$1.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $2.2 million in Q4 2024 to a low of -$3.6 million in Q4 2022.
• The 5-year median for Non Operating Income is -$19000.0 (2023), against an average of -$178411.8.
• Across the five-year window, Non Operating Income soared 12266.67% in 2024 and sank 2060.0% in 2025, its largest moves.
• Taysha Gene Therapies' Non Operating Income stood at -$3.6 million in 2022, then surged by 99.35% to -$23000.0 in 2023, then surged by 9686.96% to $2.2 million in 2024, then tumbled by 161.0% to -$1.3 million in 2025, then surged by 180.0% to $1.1 million in 2026.
• The last three Non Operating Income figures came in at $1.1 million (Q1 2026), -$1.3 million (Q4 2025), and -$37000.0 (Q3 2025), per Business Quant data.